SCHEMBL8222807

SCHEMBL8222807

O=C(Cn1nc(C(F)(F)F)c2c1CCCC2)Nc1sc2c(c1C(=O)NCc1cccnc1)CCCC2

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AMY1A P0DUB6 4/20 0.62
ALDH1A1 P00352 4/20 0.60
KDM4E B2RXH2 2/20 0.60
POLB P06746 2/20 0.60
PTK2B Q14289 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
HPGD P15428 3/20 0.59
MAPK1 P28482 1/20 0.59
RECQL P46063 1/20 0.59
HSD17B10 Q99714 1/20 0.59
GRM1 Q13255 3/20 0.59
MGAM O43451 5/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
RORC P51449 3/20 0.55
NPSR1 Q6W5P4 2/20 0.54
LMNA P02545 1/20 0.54
MAPT P10636 4/20 0.54
TP53 P04637 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8223797 0.92 GRM1 (0.59) AMY1AALDH1A1KDM4EPOLBPTK2B
SCHEMBL8225245 0.91 GRM1 (0.62) ALDH1A1SMN1; SMN2HPGDGRM1MEN1
SCHEMBL8219874 0.86 GRM1 (0.60) AMY1AALDH1A1KDM4EPOLBSMN1; SMN2
SCHEMBL15062260 0.84 POLQ (0.53) AMY1AALDH1A1KDM4EPOLBPTK2B
SCHEMBL1006724 0.84 SMN1; SMN2 (0.67) POLBSMN1; SMN2HSD17B10LMNAMAPT
SCHEMBL8223635 0.83 GRM1 (0.60) ALDH1A1SMN1; SMN2HPGDHSD17B10GRM1
SCHEMBL3452916 0.83 GRM1 (0.69) ALDH1A1POLBSMN1; SMN2HPGDGRM1
SCHEMBL8223745 0.82 GRM1 (0.70) ALDH1A1SMN1; SMN2HPGDGRM1MEN1
SCHEMBL3451925 0.81 GRM1 (0.69) ALDH1A1POLBSMN1; SMN2HPGDGRM1
SCHEMBL8223001 0.81 GRM1 (0.60) AMY1AALDH1A1KDM4EPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820707-B2 Heterocyclic derivatives N.V. ORGANON (NL) 2010-10-26 US disclosed
US-7820707-B2 Heterocyclic derivatives N.V. ORGANON (NL) 2010-10-26 US disclosed
US-20080255086-A1 Heterocyclic Derivatives N.V. ORGANON (NL) 2008-10-16 US disclosed
US-20080255086-A1 Heterocyclic Derivatives N.V. ORGANON (NL) 2008-10-16 US disclosed
WO-2008003452-A1 PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS N.V. ORGANON (NL) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255086-A1 Heterocyclic Derivatives GRIN2C, GRIN3A, GRIN1 AMY1A 3822/4885ALDH1A1 453/4885KDM4E 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.